Latest news about Natural Biocon
Natural Biocon
3.87
+0.07(+1.84%)
Company Performance:
View Company Insights1D+1.84%
1M+15.18%
6M-34.52%
1Y-65.81%
5Y-76.33%
More news about Natural Biocon
01Dec 25
Natural Biocon Reports Zero Revenue and Rs 4.37 Lakh Loss in Q2 FY2026
Natural Biocon Limited reported zero net sales for Q2 FY2026, down from Rs 473.69 lakhs in Q2 FY2025. The company posted a net loss of Rs 4.37 lakhs, compared to a profit of Rs 20.24 lakhs in the same quarter last year. For H1 FY2026, profit decreased to Rs 9.49 lakhs from Rs 29.99 lakhs, while revenue fell to Rs 166.57 lakhs from Rs 572.34 lakhs in H1 FY2025. The complete absence of revenue in Q2 raises concerns about the company's operational status and financial health.
03Jun 25
Biocon Secures Approval for Generic Liraglutide in India, Expanding Diabetes Treatment Options
Biocon has obtained regulatory approval for its generic version of Victoza (Liraglutide) to treat Type 2 diabetes in India. This approval expands Biocon's diabetes care portfolio and could potentially increase access to affordable diabetes treatment for millions of Indians. The introduction of generic Liraglutide is expected to increase competition in the diabetes care market, potentially leading to lower treatment costs and more options for patients. Launch date and pricing details are yet to be announced.
09May 25
Biocon Surpasses Expectations with Strong Q4 Results, Eyes API Business Recovery
Biocon reported a consolidated net profit of ₹3.40 billion for Q4, up from ₹1.35 billion year-over-year, exceeding market estimates. Revenue increased to ₹44.20 billion from ₹39.20 billion. The company plans to recover its API business by FY2026 and expand its GLP-1 portfolio into new markets.
28Apr 25
Biocon Biologics Advances in European Market with Positive CHMP Opinions for Biosimilar Denosumab
Biocon Biologics, a subsidiary of Biocon Limited, has received positive opinions from the Committee for Medicinal Products for Human Use (CHMP) for its biosimilar denosumab in Europe. This marks a significant step towards potential approval and market entry in the European Union for the biopharmaceutical company. The biosimilar targets various bone diseases, including osteoporosis and bone metastases. While final approval from the European Medicines Agency is still pending, this development demonstrates Biocon's capabilities in complex biosimilars and positions the company for potential entry into the European biosimilars market.
24Apr 25
Biocon Unveils Ambitious 45 Billion Rupee Fundraising Plan Amid Financial Growth
Biocon, a leading biopharmaceutical company, plans to raise up to ₹45 billion ($540 million) through securities issuance, potentially via QIP or other methods. This move comes as the company experiences significant asset growth but faces increased liabilities and cash flow challenges. Recent financial data shows a 24.44% increase in total assets and a 145.45% rise in current assets, alongside a 238.46% surge in current liabilities. The company's cash flow from operating activities has turned negative, shifting from ₹0.20 billion to -₹0.10 billion year-over-year.
Industry Peers
UPL
PI Industries
Sumitomo Chemical
Bayer Crop Science
Sharda Cropchem
Rallis
Dhanuka Agritech
NACL Industries
Bhagiradha Chemicals & Industries
Bharat Rasayan
640.90
(-0.38%)
3,000.10
(-1.56%)
472.50
(+5.23%)
4,630.70
(-1.52%)
1,066.00
(+2.53%)
262.85
(+0.40%)
1,082.50
(-1.29%)
170.79
(+6.60%)
260.25
(-0.65%)
1,375.00
(-0.65%)
Get More Market Insights with
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
